Kansas Endures Largest Tuberculosis Outbreak in Decades
Wyandotte and Johnson counties in Kansas currently face the nation’s largest tuberculosis (TB) outbreak. As of January 24, 60 active cases have been identified in Wyandotte County, along with 7 in Johnson County. Additionally, latent TB infections, a potentially dormant form that can progress to active TB, have been reported in 77 individuals in Wyandotte County and 2 in Johnson County since the start of 2024. This outbreak marks a significant public health concern, making it the largest TB event in the United States in recent history.
To address this crisis, health authorities are offering free TB testing and treatment, especially for those without insurance. They are also actively working to identify and treat close contacts of infected individuals. TB, in its active form, is contagious and can be fatal if left untreated. According to the CDC, up to 13 million people in the U.S. have latent TB, with 5-10% of them at risk of developing active TB without intervention.
Japanese Researchers Discover Compound Effective Against VRE
A groundbreaking study from Chiba University in Japan has unveiled a new compound, V-161, that targets vancomycin-resistant enterococcus (VRE). This pathogen poses a serious threat as a cause of hospital-acquired infections. The compound specifically inhibits the Na+-V-ATPase enzyme, which is essential for VRE’s survival in the human gut, while leaving beneficial bacteria unharmed.
Experiments conducted on animal models demonstrated that V-161 significantly lessened bacterial growth and colonization. V-161 functions by binding to specific regions of the Na+-V-ATPase enzyme, thereby disrupting sodium transport in VRE. The development of V-161 could introduce a novel and selective antimicrobial approach to tackling antibiotic-resistant infections.
FDA Approvals for Infectious Disease Treatments and Vaccines in Q1-Q2 2025
The FDA is nearing decisions on several promising vaccines and treatments for infectious diseases in the first half of 2025. Key among these is Bavarian Nordic’s chikungunya vaccine (CHIKV VLP), set for approval on February 14, 2025. CHIKV VLP represents a pioneering VLP-based vaccine for chikungunya virus in the U.S. Also on track for the same date is GSK’s meningococcal vaccine (ABCWY), which targets multiple strains of the disease.
Additional candidates include Merck’s monoclonal antibody for RSV (Clesrovimab), aimed at reducing RSV in both adults and infants. MenQuadfi, another meningococcal vaccine, and gepotidacin, an antibiotic for uncomplicated urinary tract infections (UTIs) in adult women, are also under review. Other notable submissions include tesamorelin F8 for managing abdominal fat in HIV patients with lipodystrophy, zoliflodacin for treating gonorrhea, and Novavax’s COVID-19 vaccine.
GAFFI Pushes Fungal Infection Awareness and Diagnostic Solutions
The Global Action Fund for Fungal Infections (GAFFI) is dedicated to bridging diagnostic gaps for fungal infections, especially in under-resourced regions of Africa. Despite challenges such as limited funding, inadequate political support, and insufficient diagnostic tools, GAFFI’s initiative, “95-95 by 2025,” aims to diagnose and treat 95% of serious fungal infections by that year.
GAFFI’s efforts encompass increasing awareness, advocating for better resource allocation, and implementing effective models for diagnosis and treatment. Collaborations with African medical schools and organizations like CDC Africa have helped raise education levels and public awareness about fungal infections.
Looking ahead, GAFFI intends to replicate successful diagnostic models across Africa, although this will require extensive resources and collaboration with stakeholders.
Read More:
Part 1: The Invisible Nature of Fungal Infections
Part 2: Diagnosis Challenges and Global Health Initiatives
Levofloxacin Shows Potential in Reducing TB Incidence, Despite V Quinn Trial Limitations
The V Quinn trial assessed levofloxacin as a preventive treatment for tuberculosis (TB) among high-risk individuals, including contacts of multidrug-resistant TB (MDR-TB) patients in Vietnam. Although the trial found that levofloxacin reduced TB incidence compared to a placebo, the results were not statistically significant.
However, levofloxacin was linked to a higher number of adverse events, and there was no emergence of fluoroquinolone resistance. Gregory Fox, PhD, suggested pooling data from the V Quinn trial with that from the TB Champ trial to enhance statistical power. This combined analysis revealed a significant reduction in TB incidence among individuals treated with levofloxacin.
While the V Quinn trial’s findings were inconclusive on their own, the pooled data offer a more reliable indication of levofloxacin’s preventive effectiveness against MDR-TB. This underscores the ongoing need for research into alternative prevention strategies for MDR-TB.
These health developments underscore the complex challenges and promising advancements in managing infectious diseases. Continuous public health interventions, scientific research, and collaboration among stakeholders are crucial in addressing these threats.
Stay informed with Archynetys for the latest updates and discoveries. Share your thoughts, questions, and follow our journey to a healthier global community.
We encourage you to comment below, subscribe to our newsletter, and share this article on your social media platforms.
